Nicholas Piramal's cyclin-dependent kinase inhibitors granted US product patent

The US Patent and Trademark Office (USPTO) has granted a product patent to Nicholas Piramal India that covers novel compounds, including the company's clinical candidate P-276-00, and processes for their preparation. These compounds are being developed as therapeutic agents useful in the treatment of cancer.

Earlier Nicholas Piramal had been granted a patent in South Africa for its CDK inhibitors.

Nicholas Piramal  says it has related national phase applications in 14 other countries. The company has filed five other patent applications covering different aspects of its CDK inhibitors.

Dr Noopur Raje from Dr Ken Anderson group from Dana Faber Cancer Institute will give an  oral presentation at the 49th annual meeting and exposition of the American Society of Haematology (ASH) being held at Atlanta, Georgia. The group has carried out independent studies on Nicholas Piramal's lead compound P-276-00 in multiple myeloma and will be presenting new data on its pre-clinical studies.

The ASH annual meeting is the premier forum for physicians and researchers to hear up-to-date developments in haematology. The event attracts over 16,000 haematologists and other health-care professionals from 100 countries around the world.

Dr. (Mrs.) Swati Piramal, director, strategic alliances and communications, Nicholas Piramal, said, "The presentation of data on pre-clinical studies at annual conference of American Society of Haematology marks an important milestone for development of NPIL's oncology compound."